Articles from Biognosys AG

MELBOURNE, Australia and ZURICH, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, IonOpticks, a world leading provider of chromatography solutions, and Biognosys, a global leader in mass spectrometry-based proteomics contract research services, announce a long-term supply agreement. Under the agreement, IonOpticks will supply Biognosys with custom chromatography columns to support the standardisation of its research services platforms and enable deeper, reproducible proteome profiling.

ZURICH, Switzerland and NEWTON, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today its participation in the 23rd Human Proteome Organization (HUPO) World Congress from October 20 to October 24 in Dresden, Germany. The company will be highlighting major scientific and technological advances for its proprietary proteomics research services and software solutions with two oral presentations, eight scientific posters, one sponsored seminar, and two invited seminar talks.

ZURICH and NEWTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and provider of software solutions for mass spectrometry-based proteomics data analysis, today announced the rollout of a Value-added Reselling agreement for Biognosys’ Spectronaut® software with Thermo Fisher Scientific.

ZURICH and NEWTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in next-generation proteomics solutions for drug discovery and development, announced today the commercial availability of NULISA proteomics assays for biomarker discovery in plasma and other biofluids. NULISA is a proprietary high-sensitivity proteomics platform developed by Alamar Biosciences. Under the strategic partnership announced earlier this year, Biognosys is a provider of choice for NULISA multiplex assay services.

ZURICH, Switzerland and NEWTON, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, has announced the company’s attendance at the American Society for Mass Spectrometry (ASMS) Annual Conference from June 2nd to June 6th in Anaheim, CA, where the company will launch Spectronaut 19 and present major scientific and technological advances for its proprietary proteomics research software, services, and data insights solutions.

ZURICH, Switzerland and NEWTON, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leader in next-generation proteomics services, software and kits for life sciences research and drug development, today announced the launch of the novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type enrichment with market leading performance and sensible, superior economics. P2-based plasma proteomics can be used for human or for animal-model proteomics studies and clinical research.

ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers. This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays. This integrated approach enhances our understanding of biomarkers by combining deep unbiased DIA-MS discovery proteomics with highly specific and ultra-sensitive mid- and high-plex NULISA assays for low-abundance proteins such as cytokines, chemokines and important disease protein biomarkers from plasma.

ZURICH, Switzerland and NEWTON, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the operational readiness of its new proteomics facility in Massachusetts. This US expansion facilitates access to select proteomics contract research organization (CRO) services for our US biopharma customers.

ZUERICH, Switzerland and CAMBRIDGE, Massachusetts, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and developer of mass spectrometry (MS)-based proteomics solutions, announced today their attendance at the Human Proteome Organization (HUPO) World Congress from September 17 to September 21 in Busan, South Korea.

HOUSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Biognosys, a leading innovator and provider of proteomics solutions, today at the American Society for Mass Spectrometry (ASMS) Annual Conference is announcing the launch of an advanced plasma proteomics offering that facilitates deep, unbiased analysis of plasma proteins on a large scale.

ZURICH, Switzerland and CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, has announced the company’s attendance at the American Society for Mass Spectrometry (ASMS) Annual Conference from June 4 to June 8 in Houston, Texas where the company will launch Spectronaut 18 and present major scientific and technological advances for its proprietary proteomics research software and services.

ZURICH, Switzerland and CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the details of their presence at the American Association for Cancer Research (AACR) Annual Meeting 2023, which will be held April 14-19, 2023 in Orlando, Florida. The company will be presenting 8 scientific posters around their three research service platforms, TrueDiscovery™, TrueTarget™, and TrueSignature™, in collaboration with leading biopharma and academic researchers.

SCHLIEREN, Switzerland and BILLERICA, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biognosys AG and Bruker Corporation (Nasdaq: BRKR) today announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys.

Spectronaut 17 features directDIA+™, the best-performing library-free workflow for DIA proteomics available on the market

ZURICH, Switzerland and CAMBRIDGE, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that they opened an office in Cambridge, Massachusetts, a global hub of pharmaceutical and biotechnology companies.